---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-013597"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:09:09.303081+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AcelRx Q1 net loss $8.2M; DSUVIA divestiture closed, Niyad EUA submitted

## Summary
- Net loss $8.2M ($0.75/share) vs $8.7M loss in Q1 2022; cash $13.4M at March 31, 2023.
- DSUVIA divestiture to Alora closed April 3; 15% royalty on commercial sales, 75% on DoD, up to $116.5M milestones.
- EUA request for Niyad (nafamostat mesylate) submitted to FDA April 27; registrational study expected H2 2023.
- Combined R&D and SG&A expenses $5.3M, up from $4.9M, driven by legal and Niyad costs.
- Recognized $7.0M impairment on net assets held for sale from DSUVIA discontinued operations.

## SEC filing metadata
- accession: 0001437749-23-013597
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774923013597/0001437749-23-013597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774923013597/acrx20230509_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-013597
- JSON: https://secwatch.observer/filing/0001437749-23-013597.json
- Plain text: https://secwatch.observer/filing/0001437749-23-013597.txt

## Key facts
- Earnings Releases
  TALPHERA, INC. reported the first quarter of 2023 results: net income $8.2 million, EPS $0.75 per basic and diluted share.
  - Period: the first quarter of 2023
  - Net income: $8.2 million
  - EPS: $0.75 per basic and diluted share
  - Result: reported results
  source text: Net loss attributable to common shareholders for the first quarter of 2023 was $8.2 million, or $0.75 per basic and diluted share, compared to a net loss of $8.7 million, or $1.19 per basic and diluted share, for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427925/000143774923013597/0001437749-23-013597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.